{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:30Z","timestamp":1787019510457,"version":"build-2736575974"},"reference-count":37,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In chronic myeloid leukemia, different methods are available to monitor the response to therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization (I-FISH), and real-time quantitative polymerase chain reaction (RT-Q-PCR). The GIMEMA CML WP (Gruppo Italiano Malattie Ematologiche Adulto Chronic Myeloid Leukemia Working Party) has performed a prospective study to compare CBA and I-FISH for the definition of complete cytogenetic response (CCgR). Samples (n = 664) were evaluated simultaneously by CBA and I-FISH. Of 537 cases in CCgR, the number of positive nuclei by I-FISH was less than 1% in 444 cases (82.7%). Of 451 cases with less than 1% positive nuclei by I-FISH, 444 (98.4%) were classified as CCgR by CBA. The major molecular response rate was significantly greater in cases with I-FISH less than 1% than in those with I-FISH 1% to 5% (66.8% vs 51.6%, P &lt; .001) and in cases with CCgR and I-FISH less than 1% than in cases with CCgR and I-FISH 1% to 5% (66.1% vs 49.4%, P = .004). I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http:\/\/www.clinicaltrials.gov as NCT00514488 and NCT00510926.<\/jats:p>","DOI":"10.1182\/blood-2009-07-229864","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T20:22:05Z","timestamp":1254428525000},"page":"4939-4943","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP"],"prefix":"10.1182","volume":"114","author":[{"given":"Nicoletta","family":"Testoni","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marzocchi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Luatti","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Amabile","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baldazzi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Stacchini","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Nanni","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, La Sapienza University, Roma;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Orbassano;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Orbassano;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Giussani","sequence":"additional","affiliation":[{"name":"Medical Genetic Laboratory, Ospedali Riuniti, Bergamo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Department of Hematology, S Eugenio, TorVergata University Hospital, Roma;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Kerim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, San Giovanni Hospital, University of Torino, Torino;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Grimoldi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pathology Unit, University of Milano, Milano;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Immunological Sciences, Division of Hematology and Transplants, University of Siena, Siena;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Crescenzi","sequence":"additional","affiliation":[{"name":"Institute of Haematology, University of Perugia, Perugia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carcassi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Medical Genetics, University of Cagliari, Cagliari;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Fondazione Policlinico San Matteo Istituto Di Ricovero e Cura a Carattere Scientifico, University of Pavia, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Bari, Bari;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Fugazza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova, Genova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Zaccaria","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department University Federico II, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, L and A Ser\u00e0gnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5405","key":"2019111805423145700_B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2019111805423145700_B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminhematol.2006.12.001","article-title":"Chronic myeloid leukemia.","volume":"44","author":"Jabbour","year":"2007","journal-title":"Semin Hematol"},{"issue":"8","key":"2019111805423145700_B3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of BCR-ABL1-positive chronic myeloid leukemia.","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111805423145700_B4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/beha.2001.0154","article-title":"Cytogenetics of chronic myeloid leukemia.","volume":"14","author":"Chase","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2019111805423145700_B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cancergencyto.2006.09.025","article-title":"\u201cHome-brew\u201d FISH assay shows higher efficiency than BCR-ABL dual-color, dual fusion probe in detecting microdeletion and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.","volume":"174","author":"Albano","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2019111805423145700_B6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2003-07-2575","article-title":"Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.","volume":"103","author":"Rosti","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111805423145700_B7","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111805423145700_B8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111805423145700_B9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V95.2.404","article-title":"Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-\u03b1 therapy or allogeneic bone marrow transplantation.","volume":"95","author":"Chomel","year":"2000","journal-title":"Blood"},{"issue":"11","key":"2019111805423145700_B10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111805423145700_B11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111805423145700_B12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111805423145700_B13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia.","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111805423145700_B14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111805423145700_B15","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111805423145700_B16","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111805423145700_B17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/sj.leu.2401163","article-title":"Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis.","volume":"12","author":"Cuneo","year":"1998","journal-title":"Leukemia"},{"issue":"2","key":"2019111805423145700_B18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1098-2264(199802)21:2<90::AID-GCC3>3.0.CO;2-2","article-title":"Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.","volume":"21","author":"M\u00fchlmann","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"2019111805423145700_B19","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V91.9.3357","article-title":"Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia.","volume":"91","author":"Dewald","year":"1998","journal-title":"Blood"},{"issue":"7","key":"2019111805423145700_B20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V92.7.2315","article-title":"A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia.","volume":"92","author":"Bu\u00f1o","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111805423145700_B21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2401383","article-title":"Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.","volume":"13","author":"Yanagi","year":"1999","journal-title":"Leukemia"},{"issue":"7","key":"2019111805423145700_B22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2000.18.7.1533","article-title":"Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia.","volume":"18","author":"Le Gouill","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111805423145700_B23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"2019111805423145700_B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-4608(02)00558-7","article-title":"Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia.","volume":"137","author":"Lesser","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"10","key":"2019111805423145700_B25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphase of peripheral blood neutrophils but not of unselected white bone marrow cytogenetics in CML patients treated with imatinib.","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"2019111805423145700_B26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2004.00287.x","article-title":"Assessment of the response to imatinib in chronic myeloid leukemia patients: comparison between the FISH, multiplex and RT-PCR methods.","volume":"73","author":"Raanani","year":"2004","journal-title":"Eur J Haematol"},{"issue":"10","key":"2019111805423145700_B27","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/10428190600783551","article-title":"Utility of peripheral blood dual color dual fusion fluorescence in situ hybridization for BCR\/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.","volume":"47","author":"Landstrom","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111805423145700_B28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3324\/haematol.11910","article-title":"Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative PCR on the International Scale for detecting residual disease in chronic myeloid leukemia.","volume":"93","author":"Lund\u00e1n","year":"2008","journal-title":"Haematologica"},{"key":"2019111805423145700_B29","article-title":"Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature.","author":"ISCN 1995","year":"1995"},{"issue":"12","key":"2019111805423145700_B30","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"issue":"6","key":"2019111805423145700_B31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2019111805423145700_B32","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"10","key":"2019111805423145700_B33","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111805423145700_B34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2019111805423145700_B35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.V96.2.777","article-title":"Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia.","volume":"96","author":"Chase","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111805423145700_B36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/sj.leu.2402963","article-title":"Patterns of BCR\/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR\/ABL+ leukemias: incidence and underlying genetic abnormalities.","volume":"17","author":"Primo","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111805423145700_B37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinb mesylate therapy in chronic myeloid leukaemia with variant Philadelphia chromosome.","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/24\/4939\/1320359\/zh804909004939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/114\/24\/4939\/1320359\/zh804909004939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T05:42:59Z","timestamp":1574055779000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/114\/24\/4939\/26599\/Chronic-myeloid-leukemia-a-prospective-comparison"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,3]]},"references-count":37,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2009,12,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-07-229864","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,3]]}}}